Black Diamond Therapeutics (NASDAQ:BDTX) Announces Quarterly Earnings Results

Black Diamond Therapeutics (NASDAQ:BDTX) announced its quarterly earnings data on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.03, Zacks reports.

Black Diamond Therapeutics Trading Down 1.1 %

Shares of Black Diamond Therapeutics stock opened at $1.88 on Friday. The business’s 50 day simple moving average is $2.23 and its 200-day simple moving average is $3.20. The stock has a market capitalization of $106.38 million, a price-to-earnings ratio of -1.41 and a beta of 2.52. Black Diamond Therapeutics has a twelve month low of $1.77 and a twelve month high of $7.66.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on BDTX. Stifel Nicolaus cut their price objective on Black Diamond Therapeutics from $16.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday. Wedbush reiterated an “outperform” rating and set a $11.00 price target (down from $16.00) on shares of Black Diamond Therapeutics in a research report on Friday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $14.40.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.